BostonGene's Involvement in the EFLM Strategic Conference
BostonGene, a forward-thinking leader in artificial intelligence-driven molecular and immune profiling solutions, is gearing up to participate in the European Federation of Laboratory Medicine (EFLM) Strategic Conference 2024. This important event aims to shape the future of laboratory medicine with advanced, value-based approaches and integrated diagnostic strategies.
Keynote Talk by Joe Lennerz
On September 23, Joe Lennerz, MD, PhD, who serves as BostonGene's Chief Scientific Officer, will present an important keynote titled "Integrated Diagnostics." This session is scheduled for 2:30 PM to 3:00 PM and will explore how disease-specific diagnostic pathways can improve patient outcomes while also reducing healthcare costs. Dr. Lennerz's presentation promises valuable insights into how to optimize service delivery through collaboration across disciplines and the effective use of real-world data.
The EFLM Conference's Theme
The theme for this year's conference, "A Vision to the Future: Value-Based Laboratory Medicine," reflects a conscious shift toward innovative strategies for implementing integrated diagnostics in clinical practice. With a focus on holistic approaches, the conference aims to promote communication and teamwork among diverse specialists in laboratory medicine, enhancing the level of patient care provided.
Progress in Integrated Diagnostics
During the conference, Dr. Lennerz will chair a meeting for the Integrated Diagnostics Task Group. This session will highlight the latest advancements and practices in integrated diagnostics, fostering a dialogue between both in-person and virtual attendees. The goal is to cultivate a collaborative environment for researchers and practitioners who are dedicated to the growth of this important field.
BostonGene's Ongoing Commitment to Innovation
BostonGene's participation in this key event showcases the company's unwavering commitment to advancing laboratory medicine and integrated diagnostics. Their contributions will be featured in the "Clinical Chemistry and Laboratory Medicine" journal, further solidifying their impactful role in this rapidly progressing sector.
Contact Details
If you would like more information or would like to schedule a meeting with BostonGene during the conference, the contact person is Maria Proia. Interested individuals are encouraged to reach out for any inquiries regarding scheduling or potential collaborations.
About BostonGene Corporation
Founded in 2015, BostonGene Corporation is a groundbreaking biotechnology company that operates at the intersection of technology and biology, with the mission of revolutionizing and personalizing cancer medicine. The company consistently pushes the envelope in innovation to enhance patient care and facilitate drug development. Utilizing an AI-powered multiomics platform, BostonGene analyzes molecular profiles from cancer patients to pinpoint essential disease drivers and identify effective treatment options. Their advanced bioanalytics, along with an indication-specific cancer library and a CLIA-certified and CAP-accredited laboratory, empower them to deliver precise insights that push forward precision medicine and encourage advancements in oncology research.
Frequently Asked Questions
What is the focus of BostonGene's participation in the conference?
BostonGene aims to advance integrated diagnostics and improve patient care through innovative approaches in laboratory medicine.
Who is presenting at the EFLM Strategic Conference?
Joe Lennerz, MD, PhD, who is BostonGene's Chief Scientific Officer, will present a keynote on integrated diagnostics.
What is the theme of the EFLM conference?
The conference theme is "A Vision to the Future: Value-Based Laboratory Medicine," highlighting innovative strategies for laboratory practice.
How can attendees schedule a meeting with BostonGene?
Attendees can reach out to Maria Proia for scheduling meetings at the event.
What type of innovations does BostonGene focus on?
BostonGene specializes in innovations in cancer medicine through AI-powered molecular profiling and personalized treatment solutions.
